{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:55:46Z","timestamp":1792090546309,"version":"4.4.0"},"reference-count":256,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Portuguesa de Cardiologia"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.repc.2024.11.009","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T11:11:22Z","timestamp":1739531482000},"page":"7-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"S1","title":["Portuguese recommendations for the management of transthyretin amyloid cardiomyopathy (Part 1 of 2): Screening, diagnosis and treatment. Developed by the Task Force on the management of transthyretin amyloid cardiomyopathy of the Working Group on Myocardial and Pericardial Diseases of the Portuguese Society of Cardiology"],"prefix":"10.1016","volume":"44","author":[{"given":"Nuno","family":"Marques","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00edlvia","family":"Aguiar Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Cordeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Menezes Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Bento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulce","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Cardim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00eds","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.repc.2024.11.009_bib1000","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2024.11.009_bib1005","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2024.11.009_bib1010","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2024.11.009_bib1015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2024.11.009_bib1020","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/13506129.2023.2229484","article-title":"Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay","volume":"30","author":"Coelho","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.009_bib1025","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jaccao.2021.08.009","article-title":"Temporal trends of wild-type transthyretin amyloid cardiomyopathy in the transthyretin amyloidosis outcomes survey","volume":"3","author":"Nativi-Nicolau","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.repc.2024.11.009_bib1030","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijcard.2019.12.063","article-title":"Diagnostic delay in wild type transthyretin cardiac amyloidosis \u2013 a clinical challenge","volume":"304","author":"Ladefoged","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1035","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2024.11.009_bib1040","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.hlc.2019.11.019","article-title":"Amyloid cardiomyopathy","volume":"29","author":"Bart","year":"2020","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.repc.2024.11.009_bib1045","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3390\/biomedicines10071566","article-title":"Re-definition of the epidemiology of cardiac amyloidosis","volume":"10","author":"Rossi","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.repc.2024.11.009_bib1050","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1055","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2024.11.009_bib1060","doi-asserted-by":"crossref","first-page":"361","DOI":"10.26599\/1671-5411.2023.05.006","article-title":"Cardiac amyloidosis: state-of-the-art review","volume":"20","author":"Bukhari","year":"2023","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1065","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1070","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1075","doi-asserted-by":"crossref","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1080","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14797\/mdcvj.1066","article-title":"ATTR epidemiology genetics, and prognostic factors","volume":"18","author":"Obi","year":"2022","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"10.1016\/j.repc.2024.11.009_bib1085","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","article-title":"Transthyretin cardiac amyloidosis","volume":"118","author":"Porcari","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.repc.2024.11.009_bib1090","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy","volume":"25","author":"Porcari","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1095","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/13506129.2019.1640672","article-title":"A new era of amyloidosis: the trends at a major US referral centre","volume":"26","author":"Staron","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.009_bib1100","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2024.11.009_bib1105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2024.11.009_bib1110","first-page":"e242190","article-title":"Prevalence cardiac phenotype, and outcomes of transthyretin variants in the UK Biobank Population","volume":"28","author":"Aung","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1115","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000490553","article-title":"Epidemiology of transthyretin familial amyloid polyneuropathy in Portugal: a nationwide study","volume":"51","author":"In\u00eas","year":"2018","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.repc.2024.11.009_bib1120","doi-asserted-by":"crossref","first-page":"e003356","DOI":"10.1161\/CIRCGEN.121.003356","article-title":"Prevalence and outcomes of p.Val142Ile TTR amyloidosis cardiomyopathy: a systematic review","volume":"14","author":"Chandrashekar","year":"2021","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.repc.2024.11.009_bib1125","doi-asserted-by":"crossref","first-page":"e028973","DOI":"10.1161\/JAHA.122.028973","article-title":"Clinical penetrance of the transthyretin V122I variant in older black patients with heart failure: the SCAN-MP (screening for cardiac amyloidosis with nuclear imaging in minority populations) study","volume":"12","author":"Madhani","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.repc.2024.11.009_bib1130","first-page":"e63673","article-title":"Cardiac amyloidosis: a comprehensive review of pathophysiology, diagnostic approach applications of artificial intelligence, and management strategies","volume":"16","author":"Ahammed","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.repc.2024.11.009_bib1135","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ejhf.3088","article-title":"Deep phenotyping of p. (V142I)-associated variant transthyretin amyloid cardiomyopathy: distinct from wild-type transthyretin amyloidosis?","volume":"26","author":"Razvi","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1140","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2217\/ahe.13.10","article-title":"Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center","volume":"9","author":"Givens","year":"2013","journal-title":"Aging Health"},{"key":"10.1016\/j.repc.2024.11.009_bib1145","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.acvd.2023.07.003","article-title":"Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France","volume":"116","author":"Damy","year":"2023","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.repc.2024.11.009_bib1150","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJMc1917321","article-title":"Epidemiologic and survival trends in amyloidosis, 1987\u20132019","volume":"382","author":"Ravichandran","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2024.11.009_bib1155","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10741-023-10339-w","article-title":"Sex differences in transthyretin cardiac amyloidosis","volume":"29","author":"Aimo","year":"2024","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.repc.2024.11.009_bib1160","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1002\/ejhf.2646","article-title":"Sex differences among patients with transthyretin amyloid cardiomyopathy \u2013 from diagnosis to prognosis","volume":"24","author":"Patel","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1165","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jchf.2021.05.005","article-title":"Sex-related risk of cardiac involvement in hereditary transthyretin amyloidosis: insights from THAOS","volume":"9","author":"Caponetti","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1170","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40119-022-00265-7","article-title":"Sex differences in wild-type transthyretin amyloidosis: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"11","author":"Campbell","year":"2022","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.repc.2024.11.009_bib1175","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann Med"},{"key":"10.1016\/j.repc.2024.11.009_bib1180","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/eurjpc\/zwae093","article-title":"Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study","volume":"31","author":"Aimo","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1185","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"6","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1190","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2024.11.009_bib1195","article-title":"Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study","author":"Garc\u00eda-Pav\u00eda","year":"2024","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.repc.2024.11.009_bib1200","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/HPC.0000000000000183","article-title":"Transthyretin cardiac amyloidosis as diagnosed by 99mTc-PYP scanning in patients with acute heart failure and preserved ejection fraction","volume":"18","author":"Lo Presti","year":"2019","journal-title":"Crit Pathw Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1205","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/14796678.2024.2393031","article-title":"Transthyretin amyloid cardiomyopathy in severe aortic stenosis submitted to valve replacement: a multicenter study","volume":"20","author":"Pereira","year":"2024","journal-title":"Future Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1210","doi-asserted-by":"crossref","first-page":"e030271","DOI":"10.1161\/JAHA.123.030271","article-title":"Amyloid transthyretin cardiomyopathy in elderly patients with aortic stenosis undergoing transcatheter aortic valve implantation","volume":"12","author":"Dobner","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.repc.2024.11.009_bib1215","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2024.11.009_bib1220","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","article-title":"Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis","volume":"77","author":"Nitsche","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1225","doi-asserted-by":"crossref","first-page":"e005066","DOI":"10.1161\/CIRCIMAGING.116.005066","article-title":"Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement","volume":"9","author":"Treibel","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1230","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1002\/ehf2.14971","article-title":"Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy","volume":"11","author":"Garcia-Pavia","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1235","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/13506129.2017.1322573","article-title":"Transthyretin amyloidosis: a phenocopy of hypertrophic cardiomyopathy","volume":"24","author":"Vermeer","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.009_bib1240","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ejhf.1742","article-title":"Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies","volume":"22","author":"Milandri","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1245","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ehf2.14173","article-title":"Identification of wild-type transthyretin cardiac amyloidosis in patients with carpal tunnel syndrome surgery (CACTuS)","volume":"10","author":"Ladefoged","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1250","doi-asserted-by":"crossref","first-page":"949401","DOI":"10.3389\/fneur.2022.949401","article-title":"The frequency of V122I transthyretin mutation in a cohort of African American individuals with bilateral carpal tunnel syndrome","volume":"13","author":"Shije","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.repc.2024.11.009_bib1255","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1253\/circrep.CR-21-0046","article-title":"Tenosynovial and cardiac transthyretin amyloidosis in Japanese patients undergoing carpal tunnel release","volume":"3","author":"Sugiura","year":"2021","journal-title":"Circ Rep"},{"key":"10.1016\/j.repc.2024.11.009_bib1260","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.humpath.2011.03.004","article-title":"High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly","volume":"42","author":"Sekijima","year":"2011","journal-title":"Hum Pathol"},{"key":"10.1016\/j.repc.2024.11.009_bib1265","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ijcard.2020.12.044","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in male patients who underwent bilateral carpal tunnel surgery: the ACTUAL study","volume":"329","author":"Vianello","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1270","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/ejhf.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1275","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1080\/13506129.2019.1625322","article-title":"Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders","volume":"26","author":"L\u00f3pez-Sainz","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.009_bib1280","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jcmg.2014.03.004","article-title":"Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy","volume":"7","author":"Longhi","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1285","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","article-title":"Transthyretin-related amyloidoses and the heart: a clinical overview","volume":"7","author":"Rapezzi","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1290","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/ejhf.2566","article-title":"Systemic embolism in amyloid transthyretin cardiomyopathy","volume":"24","author":"Vilches","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1295","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jacc.2019.01.035","article-title":"High prevalence of intracardiac thrombi in cardiac amyloidosis","volume":"73","author":"Martinez-Naharro","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1300","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2018.1556156","article-title":"Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations","volume":"26","author":"Concei\u00e7\u00e3o","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.009_bib1305","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10741-015-9480-0","article-title":"Cardiac amyloidosis: the great pretender","volume":"20","author":"Rapezzi","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.repc.2024.11.009_bib1310","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40119-023-00344-3","article-title":"Clinical and genotype characteristics and symptom migration in patients with mixed phenotype transthyretin amyloidosis from the transthyretin amyloidosis outcomes survey","volume":"13","author":"Gonz\u00e1lez-Moreno","year":"2024","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.repc.2024.11.009_bib1315","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/13506129.2019.1627312","article-title":"Assessment of patients with hereditary transthyretin amyloidosis \u2013 understanding the impact of management and disease progression","volume":"26","author":"Concei\u00e7\u00e3o","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.009_bib1320","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2024.11.009_bib1325","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13023-017-0726-x","article-title":"Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm","volume":"13","author":"Sekijima","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.repc.2024.11.009_bib1330","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.repc.2024.11.009_bib1335","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s40120-021-00258-z","article-title":"Characteristics of patients with late- vs early-onset Val30Met transthyretin amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"10","author":"Waddington-Cruz","year":"2021","journal-title":"Neurol Ther"},{"key":"10.1016\/j.repc.2024.11.009_bib1340","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s13023-023-02962-5","article-title":"A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"18","author":"Gentile","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.repc.2024.11.009_bib1345","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/13506120600876849","article-title":"Myocardial hypertrophy and function are related to age at onset in familial amyloidotic polyneuropathy","volume":"13","author":"Suhr","year":"2006","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.009_bib1350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173086","article-title":"Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis \u2013 report from the Transthyretin Amyloidosis Outcome Survey (THAOS)","volume":"12","author":"Kristen","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.repc.2024.11.009_bib1355","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/jnnp-2011-301299","article-title":"Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas","volume":"83","author":"Koike","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.repc.2024.11.009_bib1360","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cardfail.2021.09.015","article-title":"Clinical implications of the amyloidogenic V122I transthyretin variant in the general population","volume":"28","author":"Kozlitina","year":"2022","journal-title":"J Card Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1365","doi-asserted-by":"crossref","first-page":"e2036","DOI":"10.1212\/WNL.0000000000207158","article-title":"Phenotypes associated with the Val122Ile, Leu58His, and late-onset Val30Met variants in patients with hereditary transthyretin amyloidosis","volume":"100","author":"Zampino","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.repc.2024.11.009_bib1370","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/03009734.2014.895786","article-title":"Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis","volume":"119","author":"Westermark","year":"2014","journal-title":"Ups J Med Sci"},{"key":"10.1016\/j.repc.2024.11.009_bib1375","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2017.9236","article-title":"Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis","volume":"318","author":"Geller","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.repc.2024.11.009_bib1380","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.jaccao.2023.05.012","article-title":"Prospective screening for transthyretin cardiac amyloidosis in spinal stenosis surgery patients: results of the CASS study","volume":"5","author":"Debonnaire","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.repc.2024.11.009_bib1385","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths","volume":"38","author":"Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Eur Heart J"},{"issue":"Suppl. I","key":"10.1016\/j.repc.2024.11.009_bib1390","doi-asserted-by":"crossref","first-page":"I131","DOI":"10.1093\/eurheartjsupp\/suac104","article-title":"The treatment of amyloidosis is being refined","volume":"24","author":"Cantone","year":"2022","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.repc.2024.11.009_bib1395","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2024.11.009_bib1400","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00392-020-01799-3","article-title":"Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK)","volume":"110","author":"Yilmaz","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1405","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.cjca.2019.12.034","article-title":"Canadian Cardiovascular Society\/Canadian Heart Failure Society Joint Position Statement on the evaluation and management of patients with cardiac amyloidosis","volume":"36","author":"Fine","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1410","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1253\/circj.CJ-20-0110","article-title":"JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis","volume":"84","author":"Kitaoka","year":"2020","journal-title":"Circ J"},{"key":"10.1016\/j.repc.2024.11.009_bib1415","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2022.01.036","article-title":"Critical comparison of documents from scientific societies on cardiac amyloidosis: JACC state-of-the-art review","volume":"79","author":"Rapezzi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1420","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/ehjci\/jead032","article-title":"Prevalence and significance of relative apical sparing in aortic stenosis: insights from an echo and cardiovascular magnetic resonance study of patients referred for surgical aortic valve replacement","volume":"24","author":"Abecasis","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1425","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/heartjnl-2021-319697","article-title":"Incident aortic stenosis in 49449 men and 42229 women investigated with routine echocardiography","volume":"108","author":"Stewart","year":"2022","journal-title":"Heart"},{"key":"10.1016\/j.repc.2024.11.009_bib1430","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1002\/ejhf.1756","article-title":"Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome","volume":"22","author":"Nitsche","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1435","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaccao.2021.08.008","article-title":"Concomitant transthyretin amyloidosis and severe aortic stenosis in elderly Indian population: a pilot study","volume":"3","author":"Singal","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.repc.2024.11.009_bib1440","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1007\/s00259-023-06374-2","article-title":"Prevalence of ATTR-CA and high-risk features to guide testing in patients referred for TAVR","volume":"50","author":"Abadie","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1445","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1093\/eurheartj\/ehaa170","article-title":"Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation","volume":"41","author":"Scully","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2024.11.009_bib1450","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3390\/jcm13030671","article-title":"Screening for occult transthyretin amyloidosis in patients with severe aortic stenosis and amyloid red flags","volume":"13","author":"Jakstaite","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.repc.2024.11.009_bib1455","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.acvd.2024.04.007","article-title":"Cardiac amyloidosis prevalence and 1-year outcome in patients with aortic stenosis undergoing transaortic valve implantation: findings from the CAMPOS-TAVI study","volume":"117","author":"Costa","year":"2024","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.repc.2024.11.009_bib1460","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jcmg.2015.04.012","article-title":"Coexistence of degenerative aortic stenosis and wild-type transthyretin-related cardiac amyloidosis","volume":"9","author":"Longhi","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1465","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/ehf2.14709","article-title":"Histological assessment of cardiac amyloidosis in patients undergoing transcatheter aortic valve replacement","volume":"11","author":"Beuthner","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1470","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12968-017-0415-x","article-title":"Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis","volume":"19","author":"Cavalcante","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.repc.2024.11.009_bib1475","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/ehjci\/jeac146","article-title":"Echocardiographic predictors of presence of cardiac amyloidosis in aortic stenosis","volume":"23","author":"Jaiswal","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1480","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/ejhf.1974","article-title":"Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis","volume":"23","author":"Rosenblum","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1485","doi-asserted-by":"crossref","first-page":"e008193","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1490","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/j.jcmg.2020.05.029","article-title":"Identifying cardiac amyloid in aortic stenosis: ECV quantification by CT in TAVR patients","volume":"13","author":"Scully","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1495","doi-asserted-by":"crossref","first-page":"e010358","DOI":"10.1161\/CIRCIMAGING.119.010358","article-title":"Quantification of myocardial extracellular volume with planning computed tomography for transcatheter aortic valve replacement to identify occult cardiac amyloidosis in patients with severe aortic stenosis","volume":"13","author":"Oda","year":"2020","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1500","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jcmg.2023.10.008","article-title":"Clinical utility of computed tomography-derived myocardial extracellular volume fraction: a systematic review and meta-analysis","volume":"17","author":"Kato","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1505","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jcct.2015.07.001","article-title":"Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis","volume":"9","author":"Treibel","year":"2015","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.repc.2024.11.009_bib1510","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jcmg.2020.03.010","article-title":"Native T1 mapping extracellular volume mapping, and late gadolinium enhancement in cardiac amyloidosis: a meta-analysis","volume":"13","author":"Pan","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1515","doi-asserted-by":"crossref","first-page":"e230425","DOI":"10.1148\/radiol.230425","article-title":"Routine 4D cardiac CT to identify concomitant transthyretin amyloid cardiomyopathy in older adults with severe aortic stenosis","volume":"309","author":"Bernhard","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.repc.2024.11.009_bib1520","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","article-title":"Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness","volume":"37","author":"Damy","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2024.11.009_bib1525","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/13506129.2019.1665996","article-title":"Prevalence of TTR variants detected by whole-exome sequencing in hypertrophic cardiomyopathy","volume":"26","author":"Lopes","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.009_bib1530","doi-asserted-by":"crossref","first-page":"e014938","DOI":"10.1161\/CIRCIMAGING.122.014938","article-title":"Identification of transthyretin cardiac amyloidosis among patients previously diagnosed with hypertrophic cardiomyopathy","volume":"15","author":"Rowin","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1535","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s10554-024-03158-z","article-title":"Transthyretin amyloid cardiomyopathy in patients with unexplained increased left ventricular wall thickness","volume":"40","author":"Holcman","year":"2024","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1540","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijcard.2019.07.051","article-title":"Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy","volume":"300","author":"Maurizi","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1545","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/ejhf.2504","article-title":"Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from phase 2 of the AC-TIVE study, an Italian nationwide survey","volume":"24","author":"Merlo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1550","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/ehf2.14645","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in pacemaker patients","volume":"11","author":"Aaseth","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1555","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2024.11.009_bib1560","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ejhf.3186","article-title":"Prevalence of wild-type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction: results of the Amylo-VIP-HF study","volume":"26","author":"Tubben","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1565","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/ehf2.13110","article-title":"Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic","volume":"8","author":"Lindmark","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1570","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s10554-016-0915-z","article-title":"Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy","volume":"32","author":"Bennani Smires","year":"2016","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1575","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.3390\/jcm12062273","article-title":"Estimating the prevalence of cardiac amyloidosis in old patients with heart failure-barriers and opportunities for improvement: the PREVAMIC study","volume":"12","author":"Ruiz-Hueso","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.repc.2024.11.009_bib1580","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","article-title":"Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis","volume":"8","author":"Hahn","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1585","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1002\/ehf2.13360","article-title":"Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy","volume":"8","author":"Devesa","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1590","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2024.11.009_bib1595","first-page":"e000030","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2 \u2013 diagnostic criteria and appropriate utilization","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1600","first-page":"e000029","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2 \u2013 evidence base and standardized methods of imaging","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1605","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/clc.22368","article-title":"Hospital volume and cardiac complications of endomyocardial biopsy: a retrospective cohort study of 9508 adult patients using a nationwide inpatient database in Japan","volume":"38","author":"Isogai","year":"2015","journal-title":"Clin Cardiol"},{"issue":"S1","key":"10.1016\/j.repc.2024.11.009_bib1610","article-title":"Safety and value of endomyocardial biopsy in cardiac amyloidosis","volume":"17","author":"Falk","year":"2010","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.009_bib1615","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000508022","article-title":"Confirming the diagnosis of amyloidosis","volume":"143","author":"Wisniowski","year":"2020","journal-title":"Acta Haematol"},{"key":"10.1016\/j.repc.2024.11.009_bib1620","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis","volume":"38","author":"Quarta","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2024.11.009_bib1625","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jaccao.2019.08.002","article-title":"AL amyloidosis for the cardiologist and oncologist: epidemiology, diagnosis, and management","volume":"1","author":"Witteles","year":"2019","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.repc.2024.11.009_bib1630","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3109\/13506120903421850","article-title":"Usefulness of labial salivary gland biopsy in familial amyloid polyneuropathy Portuguese type","volume":"16","author":"Do Amaral","year":"2009","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.009_bib1635","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jacc.2024.01.010","article-title":"Histological typing in patients with cardiac amyloidosis: JACC review topic of the week","volume":"83","author":"Gonzalez-Lopez","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1640","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-019-0193-9","article-title":"Two types of amyloidosis presenting in a single patient: a case series","volume":"9","author":"Sidiqi","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.repc.2024.11.009_bib1645","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jaccao.2020.01.001","article-title":"Evidence of concurrent light chain and transthyretin cardiac amyloidosis in 2 patients","volume":"2","author":"Donnelly","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.repc.2024.11.009_bib1650","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s004280050471","article-title":"Highly sensitive diagnosis of amyloid and various amyloid syndromes using Congo red fluorescence","volume":"436","author":"Linke","year":"2000","journal-title":"Virchows Arch"},{"key":"10.1016\/j.repc.2024.11.009_bib1655","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/jclinpath-2014-202722","article-title":"A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue","volume":"68","author":"Gilbertson","year":"2015","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.repc.2024.11.009_bib1660","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.kint.2019.05.027","article-title":"The sensitivity and specificity of the routine kidney biopsy immunofluorescence panel are inferior to diagnosing renal immunoglobulin-derived amyloidosis by mass spectrometry","volume":"96","author":"Gonzalez Suarez","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.repc.2024.11.009_bib1665","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2014-11-609883","article-title":"A practical approach to the diagnosis of systemic amyloidoses","volume":"125","author":"Fern\u00e1ndez de Larrea","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.repc.2024.11.009_bib1670","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/13506129.2019.1688289","article-title":"Immunoelectron microscopy and mass spectrometry for classification of amyloid deposits","volume":"27","author":"Abildgaard","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.009_bib1675","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.repc.2024.11.009_bib1680","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1685","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2024.11.009_bib1690","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/ehf2.12511","article-title":"Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis","volume":"6","author":"Brownrigg","year":"2019","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1695","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s12350-020-02139-8","article-title":"Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: imaging at 1 vs 3 hours and planar vs SPECT\/CT","volume":"27","author":"Sperry","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1700","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.jacc.2020.04.022","article-title":"Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis: JACC review topic of the week","volume":"75","author":"Hanna","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1705","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1093\/eurheartj\/ehad139","article-title":"Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis","volume":"44","author":"Rauf","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2024.11.009_bib1710","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jcmg.2019.10.015","article-title":"Low sensitivity of bone scintigraphy in detecting Phe64Leu mutation-related transthyretin cardiac amyloidosis","volume":"13","author":"Musumeci","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1715","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/03009734.2015.1122687","article-title":"(99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis","volume":"121","author":"Pilebro","year":"2016","journal-title":"Ups J Med Sci"},{"key":"10.1016\/j.repc.2024.11.009_bib1720","doi-asserted-by":"crossref","first-page":"e0211983","DOI":"10.1371\/journal.pone.0211983","article-title":"Amyloid fibril composition within hereditary Val30Met (p Val50Met) transthyretin amyloidosis families","volume":"14","author":"Suhr","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.repc.2024.11.009_bib1725","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3109\/13506129.2013.797890","article-title":"Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis","volume":"20","author":"Ihse","year":"2013","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.009_bib1730","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/path.2411","article-title":"Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis","volume":"216","author":"Ihse","year":"2008","journal-title":"J Pathol"},{"key":"10.1016\/j.repc.2024.11.009_bib1735","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1740","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1373\/clinchem.2008.117143","article-title":"Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine","volume":"55","author":"Palladini","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.repc.2024.11.009_bib1745","first-page":"472","article-title":"A modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing","volume":"94","author":"Muchtar","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.repc.2024.11.009_bib1750","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008225","article-title":"Avoiding catastrophe: understanding free light chain testing in the evaluation of ATTR amyloidosis","volume":"14","author":"Witteles","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1755","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41408-022-00732-3","article-title":"Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study","volume":"12","author":"Long","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.repc.2024.11.009_bib1760","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2215\/CJN.02290508","article-title":"Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease","volume":"3","author":"Hutchison","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.repc.2024.11.009_bib1765","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5334\/gh.1262","article-title":"World Heart Federation consensus on transthyretin amyloidosis cardiomyopathy (ATTR-CM)","volume":"18","author":"Brito","year":"2023","journal-title":"Glob Heart"},{"key":"10.1016\/j.repc.2024.11.009_bib1770","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jcmg.2013.09.019","article-title":"CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis","volume":"7","author":"White","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1775","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10554-012-0042-4","article-title":"Utility of the inversion scout sequence (TI scout) in diagnosing myocardial amyloid infiltration","volume":"29","author":"Pandey","year":"2013","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1780","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","article-title":"Native T1 mapping in transthyretin amyloidosis","volume":"7","author":"Fontana","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1785","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and extracellular volume in transthyretin amyloidosis","volume":"12","author":"Martinez-Naharro","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1790","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jcmg.2012.11.013","article-title":"Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis","volume":"6","author":"Karamitsos","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"issue":"Pt 1","key":"10.1016\/j.repc.2024.11.009_bib1795","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcmg.2019.03.026","article-title":"Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis","volume":"13","author":"Baggiano","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1800","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12968-017-0389-8","volume":"19","author":"Messroghli","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.repc.2024.11.009_bib1805","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12872-016-0311-6","article-title":"Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis","volume":"16","author":"Zhao","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.repc.2024.11.009_bib1810","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00392-020-01771-1","article-title":"Diagnostic value of cardiovascular magnetic resonance in comparison to endomyocardial biopsy in cardiac amyloidosis: a multi-centre study","volume":"110","author":"Chatzantonis","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1815","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/RTI.0000000000000493","article-title":"Diagnostic performance of abnormal nulling on cardiac magnetic resonance imaging look locker inversion time sequence in differentiating cardiac amyloidosis types","volume":"35","author":"Tavoosi","year":"2020","journal-title":"J Thorac Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1820","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1002\/jmri.27459","article-title":"Reference ranges diagnostic and prognostic utility of native T1 mapping and extracellular volume for cardiac amyloidosis: a meta-analysis","volume":"53","author":"Wang","year":"2021","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1825","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.diii.2024.08.002","article-title":"Diagnostic performance and relationships of structural parameters and strain components for the diagnosis of cardiac amyloidosis with MRI","volume":"12","author":"Zaarour","year":"2024","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1830","article-title":"Cardiac MRI-derived extracellular volume fraction versus myocardium-to-lumen R1 ratio at postcontrast T1 mapping for detecting cardiac amyloidosis","volume":"5","author":"Kidoh","year":"2023","journal-title":"Radiol Cardiothorac Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1835","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2967\/jnumed.111.102053","article-title":"In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET","volume":"54","author":"Antoni","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.repc.2024.11.009_bib1840","doi-asserted-by":"crossref","first-page":"830572","DOI":"10.3389\/fcvm.2022.830572","article-title":"Diagnostic value of 11C-PIB PET\/MR in cardiac amyloidosis","volume":"9","author":"Bi","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.repc.2024.11.009_bib1845","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jacc.2019.11.037","article-title":"Pittsburgh B compound positron emission tomography in patients with AL cardiac amyloidosis","volume":"75","author":"Lee","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1850","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1007\/s00259-014-2787-6","article-title":"Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography","volume":"41","author":"Dorbala","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1855","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.114.002954","article-title":"18F-Florbetapir binds specifically to myocardial light chain and transthyretin amyloid deposits: autoradiography study","volume":"8","author":"Park","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1860","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2967\/jnumed.115.169870","article-title":"Cardiac amyloid imaging with 18F-Florbetaben PET: a pilot study","volume":"57","author":"Law","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.repc.2024.11.009_bib1865","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s12350-017-0799-x","article-title":"18Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis","volume":"25","author":"Morgenstern","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1870","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1007\/s12350-019-01885-8","article-title":"18F-sodium fluoride PET\/MRI myocardial imaging in patients with suspected cardiac amyloidosis","volume":"28","author":"Abulizi","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1875","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s12149-019-01372-7","article-title":"Amyloid PET imaging in cardiac amyloidosis: a pilot study using 18F-flutemetamol positron emission tomography","volume":"33","author":"Dietemann","year":"2019","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.repc.2024.11.009_bib1880","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.jcmg.2023.07.007","article-title":"Cardiac amyloid quantification using 124I-evuzamitide (124I-P5+14) versus 18F-florbetapir: a pilot PET\/CT study","volume":"16","author":"Clerc","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1885","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12350-016-0638-5","article-title":"Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR)","volume":"25","author":"Pilebro","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1890","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s12350-020-02356-1","article-title":"18F-fluoride PET\/MR in cardiac amyloid: a comparison study with aortic stenosis and age- and sex-matched controls","volume":"29","author":"Andrews","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1895","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12350-019-01675-2","article-title":"Examining the sensitivity of 18F-NaF PET for the imaging of cardiac amyloidosis","volume":"28","author":"Martineau","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1900","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.jacc.2016.09.953","article-title":"18F-sodium fluoride PET\/MR for the assessment of cardiac amyloidosis","volume":"68","author":"Trivieri","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1905","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jcmg.2020.02.023","article-title":"Diagnostic accuracy of [11C]PIB positron emission tomography for detection of cardiac amyloidosis","volume":"13","author":"Rosengren","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1910","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00259-019-04290-y","article-title":"Detection of cardiac amyloidosis with 18F-florbetaben-PET\/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy","volume":"46","author":"Kircher","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1915","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s12350-021-02608-8","article-title":"Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images","volume":"29","author":"Santarelli","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib1920","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fcvm.2015.00023","article-title":"A routine PET\/CT protocol with streamlined calculations for assessing cardiac amyloidosis using (18)F-florbetapir","volume":"2","author":"Osborne","year":"2015","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.repc.2024.11.009_bib1925","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00259-023-06381-3","article-title":"Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: a systematic review","volume":"51","author":"Tingen","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib1930","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jchf.2021.06.007","article-title":"Spironolactone in patients with an echocardiographic HFpEF phenotype suggestive of cardiac amyloidosis: results from TOPCAT","volume":"9","author":"Sperry","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1935","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.repc.2024.11.009_bib1940","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ehf2.14188","article-title":"SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin","volume":"10","author":"Dobner","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1945","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s11739-022-02944-8","article-title":"SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series","volume":"17","author":"Zampieri","year":"2022","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.repc.2024.11.009_bib1950","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ejhf.3198","article-title":"Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: analyses of short-term efficacy and safety","volume":"26","author":"Lang","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1955","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"sup1","key":"10.1016\/j.repc.2024.11.009_bib1960","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/13506129.2016.1272453","article-title":"Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful?","volume":"24","author":"Aus dem Siepen","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.009_bib1965","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.3390\/jcm13082257","article-title":"Prognostic value of standard heart failure medication in patients with cardiac transthyretin amyloidosis","volume":"13","author":"Aus dem Siepen","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.repc.2024.11.009_bib1970","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017335","article-title":"Cardiac resynchronization therapy for transthyretin cardiac amyloidosis","volume":"9","author":"Donnellan","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.repc.2024.11.009_bib1975","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.healun.2015.03.012","article-title":"Role of ventricular assist therapy for patients with heart failure and restrictive physiology: improving outcomes for a lethal disease","volume":"34","author":"Grupper","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.repc.2024.11.009_bib1980","doi-asserted-by":"crossref","first-page":"e007931","DOI":"10.1161\/CIRCHEARTFAILURE.120.007931","article-title":"Durable mechanical circulatory support in patients with amyloid cardiomyopathy: insights from INTERMACS","volume":"13","author":"Michelis","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib1985","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.healun.2013.01.987","article-title":"Left ventricular device implantation for advanced cardiac amyloidosis","volume":"32","author":"Swiecicki","year":"2013","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.repc.2024.11.009_bib1990","doi-asserted-by":"crossref","DOI":"10.1016\/j.healun.2024.05.010","article-title":"International Society for Heart and Lung Transplantation Guidelines for the evaluation and care of cardiac transplant candidates \u2013 2024","volume":"43","author":"Peled","year":"2024","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.repc.2024.11.009_bib1995","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.healun.2017.11.015","article-title":"Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era","volume":"37","author":"Kristen","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.repc.2024.11.009_bib2000","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jchf.2019.12.013","article-title":"Outcomes in patients with cardiac amyloidosis undergoing heart transplantation","volume":"8","author":"Barrett","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib2005","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/TP.0000000000001021","article-title":"Survival after transplantation in patients with mutations other than Val30Met: extracts from the FAP World Transplant Registry","volume":"100","author":"Suhr","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.repc.2024.11.009_bib2010","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/tri.12549","article-title":"Combined heart-liver transplantation: a single-center experience","volume":"28","author":"Careddu","year":"2015","journal-title":"Transpl Int"},{"key":"10.1016\/j.repc.2024.11.009_bib2015","author":"Aguiar Rosa","year":"2024","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib2020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.carrev.2022.04.027","article-title":"Clinical outcome of TAVR vs SAVR in patients with cardiac amyloidosis","volume":"43","author":"Khan","year":"2022","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.repc.2024.11.009_bib2025","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib2030","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2024.11.009_bib2035","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.repc.2024.11.009_bib2040","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jacc.2016.04.035","article-title":"Cardiac amyloid load: a prognostic and predictive biomarker in patients with light-chain amyloidosis","volume":"68","author":"Kristen","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib2045","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jacep.2019.10.013","article-title":"No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis","volume":"5","author":"Donnellan","year":"2019","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.repc.2024.11.009_bib2050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ehf2.13701","article-title":"Thromboembolism and bleeding in systemic amyloidosis: a review","volume":"9","author":"Nicol","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib2055","doi-asserted-by":"crossref","first-page":"742428","DOI":"10.3389\/fcvm.2021.742428","article-title":"New oral anticoagulants vs vitamin K antagonists among patients with cardiac amyloidosis: prognostic impact","volume":"8","author":"Cariou","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.repc.2024.11.009_bib2060","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13506129.2020.1810010","article-title":"Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding","volume":"28","author":"Mitrani","year":"2021","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.009_bib2065","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2024.11.009_bib2070","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib2075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/13506129.2020.1798922","article-title":"Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation","volume":"28","author":"Cappelli","year":"2021","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.009_bib2080","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial fibrillation in transthyretin cardiac amyloidosis: predictors prevalence, and efficacy of rhythm control strategies","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.repc.2024.11.009_bib2085","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2024.11.009_bib2090","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.hrthm.2015.09.016","article-title":"Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy","volume":"13","author":"Barbhaiya","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.repc.2024.11.009_bib2095","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.amjcard.2020.07.034","article-title":"Digoxin use in cardiac amyloidosis","volume":"133","author":"Donnelly","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib2100","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.hrthm.2013.10.026","article-title":"Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis","volume":"11","author":"Varr","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.repc.2024.11.009_bib2105","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijcard.2016.07.254","article-title":"Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis","volume":"222","author":"Hamon","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.repc.2024.11.009_bib2110","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/europace\/euaa094","article-title":"Outcomes in patients with cardiac amyloidosis and implantable cardioverter-defibrillator","volume":"22","author":"Kim","year":"2020","journal-title":"Europace"},{"key":"10.1016\/j.repc.2024.11.009_bib2115","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/pace.14458","article-title":"Ventricular arrhythmia burden and implantable cardioverter-defibrillator outcomes in transthyretin cardiac amyloidosis","volume":"45","author":"Brown","year":"2022","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.repc.2024.11.009_bib2120","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016038","article-title":"Survival following implantable cardioverter-defibrillator implantation in patients with amyloid cardiomyopathy","volume":"9","author":"Higgins","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.repc.2024.11.009_bib2125","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2024.11.009_bib2130","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.hrthm.2007.10.016","article-title":"Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death","volume":"5","author":"Kristen","year":"2008","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.repc.2024.11.009_bib2135","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.hrthm.2012.02.033","article-title":"Prophylactic pacemaker implantation in familial amyloid polyneuropathy","volume":"9","author":"Algalarrondo","year":"2012","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.repc.2024.11.009_bib2140","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1093\/eurheartj\/ehab364","article-title":"2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy","volume":"42","author":"Glikson","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2024.11.009_bib2145","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/ejhf.2533","article-title":"Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis","volume":"24","author":"Porcari","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib2150","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/jce.14180","article-title":"Cardiac devices in patients with transthyretin amyloidosis: impact on functional class, left ventricular function, mitral regurgitation, and mortality","volume":"30","author":"Donnellan","year":"2019","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.repc.2024.11.009_bib2155","doi-asserted-by":"crossref","first-page":"e016614","DOI":"10.1161\/JAHA.120.016614","article-title":"Specific therapy for transthyretin cardiac amyloidosis: a systematic literature review and evidence-based recommendations","volume":"9","author":"Marques","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.repc.2024.11.009_bib2160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","article-title":"Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis","volume":"5","author":"Coelho","year":"2016","journal-title":"Neurol Ther"},{"key":"10.1016\/j.repc.2024.11.009_bib2165","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.repc.2024.11.009_bib2170","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","article-title":"Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy","volume":"260","author":"Coelho","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.repc.2024.11.009_bib2175","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the tafamidis in transthyretin cardiomyopathy clinical trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib2180","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/ejhf.2974","article-title":"Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms","volume":"25","author":"Elliott","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib2185","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2967\/jnumed.122.265352","article-title":"Regression of myocardial 99mTc-DPD uptake after tafamidis treatment of cardiac transthyretin amyloidosis","volume":"64","author":"Papathanasiou","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.repc.2024.11.009_bib2190","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jcmg.2022.12.016","article-title":"Tafamidis treatment decreases 99mTc-pyrophosphate uptake in patients with hereditary Ala97Ser transthyretin amyloid cardiomyopathy","volume":"16","author":"Yu","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.repc.2024.11.009_bib2195","doi-asserted-by":"crossref","first-page":"e008381","DOI":"10.1161\/CIRCHEARTFAILURE.121.008381","article-title":"Impact of tafamidis and optimal background treatment on physical performance in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Badr Eslam","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib2200","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1021\/acs.jmedchem.8b00817","article-title":"Enthalpy-driven stabilization of transthyretin by AG10 mimics a naturally occurring genetic variant that protects from transthyretin amyloidosis","volume":"61","author":"Miller","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.repc.2024.11.009_bib2205","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/jcph.1553","article-title":"Pharmacokinetics of Patisiran, the first approved RNA interference therapy in patients with hereditary transthyretin-mediated amyloidosis","volume":"60","author":"Zhang","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.repc.2024.11.009_bib2210","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2024.11.009_bib2215","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2024.11.009_bib2220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.009_bib2225","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ejhf.3138","article-title":"Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"26","author":"Garcia-Pavia","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib2230","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/13506129.2016.1191458","article-title":"Suppressing transthyretin production in mice, monkeys and humans using 2nd-generation antisense oligonucleotides","volume":"23","author":"Ackermann","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.009_bib2235","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2024.11.009_bib2240","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","article-title":"Inotersen therapy of transthyretin amyloid cardiomyopathy","volume":"27","author":"Dasgupta","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.repc.2024.11.009_bib2245","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.repc.2024.11.009_bib2250","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2023.11.016","article-title":"Effect of eplontersen on cardiac structure and function in patients with hereditary transthyretin amyloidosis","volume":"30","author":"Masri","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.repc.2024.11.009_bib2255","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04136171?intr=eplontersen&rank=4 [Internet]. trial gov cardiottransform."},{"key":"10.1016\/j.repc.2024.11.009_bib2260","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40259-022-00550-w","article-title":"Targeting amyloid fibrils by passive immunotherapy in systemic amyloidosis","volume":"36","author":"Nuvolone","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.repc.2024.11.009_bib2265","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2024.11.009_bib2270","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2024.11.009_bib2275","article-title":"Lessons from the first-in-human in vivo CRISPR\/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy","volume":"2023","author":"Kotit","year":"2023","journal-title":"Glob Cardiol Sci Pract"}],"container-title":["Revista Portuguesa de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S087025512500023X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S087025512500023X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T14:31:30Z","timestamp":1741271490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S087025512500023X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":256,"alternative-id":["S087025512500023X"],"URL":"https:\/\/doi.org\/10.1016\/j.repc.2024.11.009","relation":{},"ISSN":["0870-2551"],"issn-type":[{"value":"0870-2551","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Portuguese recommendations for the management of transthyretin amyloid cardiomyopathy (Part 1 of 2): Screening, diagnosis and treatment. Developed by the Task Force on the management of transthyretin amyloid cardiomyopathy of the Working Group on Myocardial and Pericardial Diseases of the Portuguese Society of Cardiology","name":"articletitle","label":"Article Title"},{"value":"Revista Portuguesa de Cardiologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2024.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}